Role of angiotensin II in diabetic cardiovascular and renal disease

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 2, 2006, Pages 135-140

  Hayden, Melvin R ^a   Whaley Connell, Adam ^a   Chowdhury, Nazif ^b   Sowers, James R ^a  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin (1 7); Angiotensin II; Angiotensin converting enzyme 2; Perivascular remodeling; Podocyte

Indexed keywords

ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE;

CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PODOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TARGET ORGAN;

EID: 33646028246     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000216961.44128.9e     Document Type: Review

References (34)

1. Hayden MR, Sowers JR. Hypertension in type 2 diabetes mellitus. Insulin 2006; 1:22-37. This paper explains how a local tissue RAAS is activated in the relative normal or low-normal renin state in metabolic syndrome and type 2 diabetes mellitus.
2. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004; 17:16S-20S. An outstanding review, which details the cardiovascular effects of angiotensin II and updates the readers in this exciting area of study.
3. Michel JB. Tissue consequence of renin-angiotensin system activation. Bull Acad Natl Med 2004; 188:611-619. This article allows the reader to gain insight into the concept that the systemic RAAS and local-tissue RAAS are compartmentalized. This allows for a better understanding regarding the RAAS paradox: that a local RAAS is active in the systemic normal or low-normal renin state of the metabolic syndrome, IR, and type 2 diabetes mellitus. This is especially important in the end-organs associated with diabetic opathies complications.
4. Hayden MR, Whaley-Connell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 2005; 25: 553-569. This in-depth review discusses the important role of oxidative-redox stress and how it affects the ECM remodeling in the kidney. A tribute to the podocyte cell and its importance in the development of diabetic nephropathy and end-stage renal disease is characterized both functionally and structurally.
5. Weber KT, Brilla CG. Myocardial fibrosis and the renin-angiotensin-aldosterone system. J Cardiovasc Pharmacol 1992; 20 (Suppl. 1):S48-S54.
6. Dzau V, Chobanian AV. Atherosclerosis and coronary artery disease, Vol 1, Chapter 14. In: Fuster, V, Ross, R, Topol, EJ, editors. Renin-angiotensin system and atherosclerotic vascular disease. Philadelphia, New York Lippincott-Raven; 1996. pp. 237-242.
7. Chatziantoniou C, Dussaule JC. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol - Ren Physiol 2005; 289:227-234.
8. Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2003; 2:2.
9. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105:1656-1662.
10. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2005; 102:9056-9061.
11. Shinozaki K, Ayajiki K, Kashiwagi A, et al. Malfunction of vascular control in lifestyle-related diseases: mechanisms underlying endothelial dysfunction in the insulin-resistant state. J Pharmacol Sci 2004; 96:401-405.
12. Tyagi SC, Rodriguez W, Patel AM, et al. Hyperhomocysteinemic diabetic cardiomyopathy: oxidative stress, remodeling, and endothelial-myocyte uncoupling. J Cardiovasc Pharmacol Ther 2005; 10:1-10. This paper introduces the term 'endothelial myocyte uncoupling', associates the structural changes with light microscopy with functional changes of the myocardium with an extensive discussion of the mechanisms involved in diabetic cardiomyopathy, and relates oxidative stress to ECM remodeling between the endothelium and the myocyte.
13. Hayden MR, Tyagi SC. Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit 2003; 9:SR35-SR52.
14. Hayden MR, Tyagi SC. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol 2004; 3:1.
15. Leung PS, Carlsson PO. Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas 2005; 30:293-298.
16. Tikellis C, Cooper ME, Thomas MC. Role of the renin-angiotensin system in the endocrine pancreas: Implications for the development of diabetes. Int J Biochem Cell Biol 2005; E-pub ahead of print.
17. Tikellis C, Wookey PJ, Candido R, et al. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004; 53:989-997.
18. Zhao HL, Lai FM, Tong PC, et al. Clinicopathologic characteristics of nodular glomerulosclerosis in Chinese patients with type 2 diabetes. Am J Kidney Dis 2004; 44:1039-1049.
19. Whaley-Connell A, Sowers K, Sowers JR. Hypertension and cardiovascular disease. In: Mogenson CE, Cortes P, editors. Diabetic nephropathy, Totowa, NJ: Humana Press; 2006. In press.
20. Wolfe G. Role of reactive oxygen species in angiotensin ii-mediated renal growth, differentiation, and apoptosis. Antioxid Redox Signal 2005; 7:1337-1145.
21. Sharma R, Sharma M, Reddy S, et al. Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes. Front Biosci 2005; 11:968-976.
22. Sanchez-Lopez E, Lopez AF, Esteban V, et al. Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1alpha induction and redox mechanisms in the kidney. Antioxid Redox Signal 2005; 7:1275-1284.
23. Mifsud SA, Allen TJ, Bertram JF, et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001; 44:878-882.
24. Gross ML, El-Shakmak A, Szabo A, et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003; 46:856-868.
25. Bonnet F, Cooper ME, Kawachi H, et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44:874-877.
26. Davis BJ, Cao Z, de Gasparo M, et al. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003; 21:209-216.
27. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83:253-307.
28. Gloy J, Henger A, Fischer KG, et al. Angiotensin II depolarizes podocytes in the intact glomerulus of the rat. J Clin Invest 1997; 99:2772-2781.
29. Han SY, Kang YS, Jee JH, et al. High glucose and angiotensin II increase beta1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes. Cell Tissue Res 2005; 1-12 E-pub ahead of print. This study introduces a unifying theme between elevated glucose, angiotensin II, and podocyte damage.
30. Abbate M, Zoja C, Morigi M, et al. Transforming growth factor-beta1 is upregulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002; 161:2179-2193.
31. Durvasula RV, Petermann AT, Hiromura K, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65:30-39.
32. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54:1626-1634.
33. Brinkkoetter PT, Holtgrefe S, van der Woude FJ, Yard BA. Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes. J Am Soc Nephrol 2004; 15: 33-40.
34. Ferrario C, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005; 68:2189-2196. A very important paper on the effects of losartan, lisinopril, and their combined effects on ACE2 activity.